Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks
1. Tvardi's stock fell 84.18% to $6.58 after trial update. 2. Phase 2 REVERT trial did not meet efficacy goals. 3. Discontinuation rates higher for TTI-101 in IPF patients. 4. FVC improvement similar between placebo and treatment arms. 5. Company has $41 million to fund operations through 2026.